Editas Medicine, Inc.
A biotech company that develops treatments for serious diseases by editing genes with CRISPR, a molecular tool that snips and rewrites DNA. Founded in 2013 in Cambridge, Massachusetts, it was started by pioneers of the field including Jennifer Doudna and Feng Zhang, and its name comes from the Latin word "edit." Its medicines aim at inherited conditions such as blood disorders and cardiovascular disease.
Sold 20.8K
Sold 1.5K
Sold 938
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| O'Neill Gilmore NeilCEO, Director · 2 transactions | -7.7% | 248.3K | — | — | 20.8K |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER · 2 transactions | -2.2% | 67.3K | — | — | 1.5K |
| Parison AmySVP, Chief Financial Officer · 2 transactions | -5.9% | 15.0K | — | — | 938 |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: -23.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.